Reproductive & Genetic Hospital of CITIC-Xiangya
33
0
0
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
15.2%
5 terminated/withdrawn out of 33 trials
75.0%
-11.5% vs industry average
3%
1 trials in Phase 3/4
0%
0 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (33)
Prospective International Multi-center Clinical Trial of PGT-A Upgrade
Role: lead
Embryo Selection by Noninvasive Preimplantation Genetic Test
Role: collaborator
First Live Birth Rate With eSET After Preimplantation Methylome Screening (PIMS) Versus Conventional In-vitro Fertilization
Role: collaborator
Live Birth After Letrozole-stimulated Cycles Versus Hormone Replacement Treatment Cycles for the First Frozen Embryo Transfer in Women With PCOS
Role: lead
Cumulative Live Birth After Double Stimulation Protocol Versus Antagonist Protocol for Poor Ovarian Responders
Role: collaborator
Effect of Lifestyle and/or Metformin Intervention on Pregnancy Outcome, A Pilot Randomized Controlled Trial
Role: lead
Construction of CITIC Xiangya Assisted Reproduction Data Repository
Role: lead
A Study of Preimplantation Genetic Screening With Next Generation Sequencing Technology on Advanced Age Women
Role: lead
Detection of Microdeletions in the Azoospermia Factor (AZF) Regions in Infertile Male Patients
Role: lead
Predictive Value of New AMH Test Method for Ovarian Response
Role: lead
CLBR Per Initial Cycle With Different Starting Dose in Aged Patients With Poor Ovarian Reservation: 300IU Versus 150IU
Role: lead
Personal FET in RIF Patients According to Histological Dating of Endometrial of Natural/ Hormone Replacement Cycle
Role: lead
Study of Value of Dexamethasone Used in Ovulation Induction
Role: lead
The Relationship Between CD138 Count of Endometrium and Reproductive Outcome
Role: lead
The Mechanism of Modified Utral-long Protocol in Improving Endometrial Receptivity in Patients With PCOS and IR
Role: lead
Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient
Role: lead
A Retrospective Study on the Effect of HBA or HBB Genetic Defects on Early Embryonic Development
Role: lead
HMG Stimulation Versus HRT for Endometrial Preparation Prior to Blastocyst Transfer in Moderate to Severe IUA Patients
Role: lead
Growth Hormone Adding to Controlled Ovarian Hyperstimulation for Improving Embryo Quality
Role: lead
Recombinant LH Supplementation Timing Strategies (From Day 1 or Day 6) to a Standard GnRH Agonist Long Protocol in Subsequent COS Cycle of Older Patients With Unexpected Poor or Suboptimal Ovarian Response
Role: lead